CTT Systems AB
15.12.2021 09:41:50 CET | ACCESS Newswire | Press release
NYKÖPING, SWEDEN / ACCESSWIRE / December 15, 2021 / CTT Systems AB (STO:CTT)
CTT SYSTEMS AB ("CTT"), the market leader of aircraft humidity control system, today celebrates a milestone when receiving its 100th Inflight Humidification VIP system award.
CTT has in total received 100 Inflight Humidification VIP system awards for VIP aircraft from Airbus (ACJ) and Boeing (BBJ), including latest generation narrowbodies, such as ACJ320neo Family and BBJMAX Family, and widebodies, including ACJ350 and BBJ787.
"This is a great milestone achievement not only for CTT but also for our many completion partners involved in the completion projects," says Peter Landquist, Vice President Senior Advisor Sales of CTT Systems. "Our Inflight Humification VIP system has evolved as a common request in completion projects, especially for VIP aircraft intended for long-haul operations, and with end-customers that value good health, wellbeing and feeling at ease during and after flight. Our IFH VIP system has battle-proven performance in large VIP cabins and holds excellent reliability data."
About Humidification in large, cabin business jets and VIP aircraft
Without an efficient humidification system, the business jet cabin is far more dehydrating than any place on Earth - below 5 % RH. The Inflight Humidification VIP system generates a striking humidity increase, restoring cabin air humidity to comfort and wellbeing level, to approx. 20 - 23 percent Relative Humidity (RH). VIP and private jet passengers will benefit from reduced dry air related problems (such as fatigue, jet-lag, red eyes, dry skin, degenerated immune system) and thrive from improved wellbeing and better sleep. The CTT humidifier is based on evaporative cooling technology that effectively precludes the transfer of bacteria. The IFH system is protected by the CTT Anti-Fuselage-Condensation system to prevent moisture issues such as rain-in-the-plane.
For additional information:
Peter Landquist, VP Senior Advisor Sales, CTT Systems AB.
Tel. 0155-20 59 02 alt. Mobile. 070-665 24 45 or email: peter.landquist@ctt.se
Ola Häggfeldt, Sales Director, CTT Systems AB.
Tel. 0155-20 59 30 or email: ola.haggfeldt@ctt.se
About CTT Systems
CTT is the leading supplier of active humidity control systems in aircraft. We solve the aircraft humidity paradox - with far too dry cabin air - and too much moisture in the fuselage - causing dehydration for people onboard and excess weight in the aircraft inducing larger environmental footprint. CTT offers humidifiers and dehumidifiers available for retrofit and line-fit on commercial aircraft as well as private jets. For more information about CTT and how active humidity control products make air traveling a little more sustainable and far more pleasurable, please visit: www.ctt.se
Attachments
CTT Systems celebrates 100th Inflight Humidification VIP system award
SOURCE: CTT Systems AB
View source version on accesswire.com:
https://www.accesswire.com/677771/CTT-Systems-Celebrates-100th-Inflight-Humidification-VIP-System-Award
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release
PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path
Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans30.9.2026 15:50:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / September 30, 2026 / Innodata Inc. (Nasdaq:INOD) today announced the opening of a new R&D laboratory that is designed to generate the data needed to train the next generation of human-like robots and independently validate the performance data that robots generate internally. Innodata developed the lab in collaboration with Vicon, a leader in motion capture who consulted on the lab design and continues to provide technical consulting. The New Jersey-based lab is equipped with high-precision, low-latency infrared optical tracking cameras that measure movement down to the sub-millimeter level-a degree of accuracy that methods such as wearable inertial measurement unit (IMU) sensors and single-camera (monocular) video analysis typically cannot match. The lab addresses an urgent need for high-quality training data for humanoids, industrial robots, and other forms of physical AI. While many other data providers infer 3D motion by analyzing 2D video, Innodata
Clean Air Metals Files Interim Financial Statements for the Six Months Ended July 31, 202630.9.2026 00:45:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / September 29, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTC PINK:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the six-month period ended July 31, 2026, available for viewing on www.sedarplus.ca. Financial HighlightsTotal assets as at July 31, 2026 of $35,465,204Total cash as at July 31, 2026 of $422,500Working capital deficiency as at July 31, 2026 of $3,188,114Shareholder's equity as at July 31, 2026 of $31,803,864 During the six-month period ended July 31, 2026, the Company incurred $164,309 in cost for exploration activities at the Thunder Bay North project. During the second fiscal quarter, the Company focused on finalizing the proposed amalgamation while continuing discussions on Advanced Exploration permitting and re-assessment of past geophysical work to highlight areas of focus for drilling and geophysics in
Continent 8 and FuturePath AI Launch Future8: Accountable AI for Regulated Industries29.9.2026 15:00:00 CEST | Press release
LISBON, PT / ACCESS Newswire / September 29, 2026 / Continent 8 Technologies and FuturePath AI today launched Future8, an AI-native operating company built for regulated operators, formed as a joint venture between the two companies. Announced at SBC Summit Lisbon, Future8 combines FuturePath's enterprise AI applications platform with Continent 8's licensed global operating footprint, enabling the iGaming industry to deploy auditable AI without compromising compliance, data sovereignty and operational control. Built for highly regulated environments, Future8 enables operators to move from AI experimentation to production deployment by embedding governance, approvals and auditability into every workflow from day one. Continent 8 brings licensed data centers and a private global network spanning more than 100 locations, built over 28 years serving the biggest iGaming and online brands, along with AI-enabled Global Capability Centers in India, the Philippines and Bulgaria. The company als
Europe SPAC Summit 2026 Invites European Private Companies to Explore the SPAC Path to U.S. Public Markets29.9.2026 15:00:00 CEST | Press release
NEW YORK, NY AND ZURICH, SWITZERLAND / ACCESS Newswire / September 29, 2026 / A growing number of European companies in frontier technologies, critical minerals, advanced manufacturing, defense tech, energy, and consumer sectors are evaluating a merger with a special purpose acquisition company (SPAC) as a faster route to a U.S. listing, a valuation that reflects global investor demand, and access to follow-on capital. The Europe SPAC Summit 2026 (ESPAC'26), co-hosted by AUM Advisors and MBP Global, is inviting the CEOs, CFOs, founders, and board members of late-stage European private companies to The Dolder Grand in Zurich on Thursday, December 10, 2026, to learn how the process works and to meet the investment bankers, institutional investors, and SPAC sponsors who make these transactions happen. Attendance is by invitation only and free of charge for qualified companies. Europe's recent de-SPACs show what is possible. Kyivstar, Ukraine's largest mobile operator, listed on Nasdaq thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom